ImmunOs Therapeutics AG’s Post

One2Treat's approach supported an FDA submission highlighting the overall treatment benefits of a pivotal oncology trial. Our innovative methodology offered insights into the net treatment benefit of a drug designed to reduce the occurrence of a specific severe Adverse Event (AE) in a pivotal phase 3 oncology trial during cancer therapy. By going beyond conventional statistical analyses that primarily targeted the occurrence of this AE as the sole outcome, our approach incorporated additional key information regarding its severity and duration. This enriched post-hoc analysis led to enhancing both the statistical and clinical significance of the trial results, emphasizing the drug's efficacy regarding this AE. To learn more about our business cases, follow this link: https://lnkd.in/emq-XwrE #ClinicalResearch #OncologyTrials #Innovation

Pain is not just "whether" you suffer (yes/no) It is how much you suffer. It is how long you suffer. It is when you suffer and if you will be able to complete a treatment. In this example, we were able to capture, all these multifaceted benefits of a drug in a single analysis to support an FDA submission. #patientcentric #oncology #multipleoutcomes

Merck Expands Oncology Pipeline with Harpoon Therapeutics Acquisition 🌐 Merck has announced its acquisition of Harpoon Therapeutics ,a strategic move to diversify its oncology pipeline. Harpoon Therapeutics is renowned for its cutting-edge Tri-specific T cell Activating Construct (TriTAC) platform, a technology that uniquely harnesses the body's immune system to target and destroy cancer cells Harpoon's lead, HPN328, targets delta-like ligand 3 (DLL3), significant in small cell lung cancer (SCLC) and neuroendocrine tumors. It's under a Phase 1/2 trial, exploring its efficacy both as a monotherapy and combined with atezolizumab in SCLC patients. October 2023 brought promising interim data for HPN328, especially in SCLC and neuroendocrine tumors. Moreover, Harpoon's pipeline includes HPN217 for relapsed/refractory multiple myeloma, currently in Phase 1 trials, and HPN601, a preclinical candidate targeting EpCAM in certain tumors. This acquisition indicates Merck's dedication to pushing the boundaries of cancer therapy. #cancertherapy #pharmanews

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/gA3s6Gh7

According to the American Cancer Society, out of the total lung cancer cases, approximately 80─85% of lung cancers are NSCLC. SKB264, a third-generation ADC, in combination with KL-A167, has exhibited promising efficacy in Phase II studies for treatment-naive advanced NSCLC patients. The therapy demonstrated high response rates, favorable disease control, and a manageable safety profile. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage! https://lnkd.in/gwXQzR_f #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

At #AmplityHealth, our contract sales, medical, and communications experts have a front-row seat in advancing #immunotherapy and #precisionmedicine to combat cancer more effectively with our biopharma clients. Here are some key highlights from #ASCO24 Day 1: - Discussion of newly FDA-approved oncology agents - Presentation of 5 years of data from the CROWN study comparing lorlatinib and crizotinib in new patients with advanced ALK-positive non-small cell lung cancer - Analysis of research into whether circulating tumor DNA can help predict the effectiveness of neoadjuvant chemotherapy and evaluate the prognosis for those with early breast cancer View our full Day 1 summary and join our mailing list for updates: https://lnkd.in/euzvmUPG

Speculative picks for 2024. Do your own reseach, of course. These are Phase III stage biotechs with apparently effective cancer drugs with virtually no side effects. GLSI - Breast cancer HER2 vaccine phase III trial underway with possible marketing opportunity halfway through trial. IMMP - Phase III trial of drug that enhances performance of blockbuster Keytruda. Expect buyout... at some point.

𝐖𝐨𝐫𝐥𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲 2024 is being observed today to raise awareness of cancer, the second leading cause of global mortality. Worldwide, the prominent cancers include lung, breast, liver, head and neck and colorectal cancer. Understanding each cancer type is crucial for effective prevention and treatment. On this 𝐖𝐨𝐫𝐥𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐚𝐲, let's unite with a collective vision—a future free from the grips of cancer. By working together, we can turn this vision into a reality and create a world without the burden of cancer. #GMPPharmaceuticals #pharmaceuticals ##WorldCancerDay #CancerAwareness #FightCancer #BeatCancer

#MemberNews - Seagen and Astellas’-partnered cancer drug Padcev has chalked up a key trial win, in combination with Merck's Keytruda, in previously untreated metastatic bladder cancer. In the study, Seagen and Astellas’ antibody-drug conjugate Padcev and Merck’s PD-1 superstar Keytruda scored on both overall survival and progression-free survival compared with chemotherapy. The results could open the combo up to patients who are eligible for platinum-based chemotherapies cisplatin or carboplatin, regardless of their PD-L1 status. https://lnkd.in/eEutxD2h #LifeScienceWA #Seagen #Padcev #Keytruda #bladdercancer #cancerresearch

Another successful meeting with Rep. Velazquez’s office! My own district 😎 HOPA colleagues and I keep advocating for our cancer patients! We discussed how The Cancer Drug Parity Act will improve the lives of cancer patients and what can be done to avoid continuous drug shortages. #hopahillday! Hematology/Oncology Pharmacy Association (HOPA) #pharmacy #pharmacists #cancer #oncology #oncologyresearch